Your kidneys are quiet overachievers. These two fist-sized organs filter waste, balance fluids and minerals, help regulate blood pressure, support red blood cell production, and generally keep the body’s internal housekeeping from becoming a disaster. Unfortunately, kidney cancer may develop without interfering with those duties enough to cause obvious early symptoms.
Kidney cancer is considerably more common in men than in women. Recent U.S. surveillance data show an age-adjusted incidence rate of approximately 24.4 cases per 100,000 males, compared with 12.3 per 100,000 females. That does not mean men experience a special “male” form of the disease. The major tumor types, symptoms, diagnostic tests, and treatments are largely the same across sexes. The difference is that men are diagnosed more often and may have greater exposure to certain risk factors, including smoking and hazardous workplace chemicals.
Understanding the warning signs matters, but so does understanding their limitations. Early kidney cancer often causes no noticeable problems. A person may feel perfectly healthy while a small tumor quietly minds its own very unwanted business. Many kidney tumors are therefore discovered during imaging performed for an unrelated issue.
What Is Male Kidney Cancer?
Kidney cancer begins when abnormal cells in a kidney grow uncontrollably and form a tumor. In adults, the most common form is renal cell carcinoma, or RCC, which begins in the lining of tiny kidney tubules. RCC accounts for roughly nine out of every ten kidney cancer diagnoses.
Common renal cell carcinoma subtypes
- Clear cell renal cell carcinoma: The most common subtype, named for the clear appearance of its cells under a microscope.
- Papillary renal cell carcinoma: A subtype that forms finger-like projections and may be associated with inherited syndromes in some families.
- Chromophobe renal cell carcinoma: A less common form that is often diagnosed before it spreads.
- Rare subtypes: These include collecting duct carcinoma, translocation-associated tumors, and renal medullary carcinoma.
Cancer of the renal pelvis, where urine collects before entering the ureter, is biologically different from RCC. It is generally classified and treated more like urothelial or bladder cancer. That distinction is one reason a precise pathology report is more than medical paperwork with impressive vocabularyit directly affects treatment.
Why Is Kidney Cancer More Common in Men?
Researchers have not identified one simple explanation for the higher kidney cancer rate in men. The difference probably results from several overlapping influences, including historical smoking patterns, occupational exposures, body weight, blood pressure, hormones, genetics, and differences in health care behavior.
Men have traditionally been more likely to work in industries involving certain solvents, metals, petroleum products, and manufacturing chemicals. They may also postpone medical visits, especially when symptoms seem minor or embarrassing. Ignoring blood in the urine because it happened “just once” is not a toughness contest anyone wins.
Kidney cancer is diagnosed most frequently in older adults, with the largest proportion of U.S. cases occurring between ages 65 and 74. However, younger men can develop it, particularly when an inherited cancer syndrome or sickle cell trait is involved.
Signs and Symptoms of Kidney Cancer in Men
Small kidney tumors often produce no symptoms because the kidneys sit deep inside the abdomen and have considerable reserve capacity. Symptoms are more likely to appear as a tumor grows, affects nearby structures, causes bleeding, or spreads to another area.
Blood in the urine
Hematuria, or blood in the urine, is the best-known kidney cancer warning sign. Urine may look pink, red, rust-colored, or similar to cola. The bleeding may appear once, disappear, and return later.
Blood in the urine can also result from kidney stones, urinary infections, an enlarged prostate, strenuous exercise, bladder conditions, or certain medications. Nevertheless, visible blood should always be medically evaluated, even when it is painless or clears up quickly.
Persistent side or back pain
Kidney cancer may cause a dull, persistent ache in the flankthe area between the ribs and hipor in the back or abdomen. Unlike a pulled muscle, cancer-related discomfort may not improve when a person stretches, changes position, or gives the couch a serious weekend workout.
Sudden, severe, wave-like pain is more characteristic of a kidney stone. Symptoms alone, however, cannot reliably identify the cause.
A lump or swelling
A large tumor can occasionally create a noticeable mass in the side, back, or upper abdomen. Because the kidneys are located deep inside the body, most small tumors cannot be felt during a routine physical examination.
Unexplained weight loss or poor appetite
Losing weight without changing eating or exercise habits may signal that the body is responding to a serious illness. Reduced appetite can occur as cancer affects metabolism, inflammation, or overall energy levels.
Fatigue and anemia
Persistent exhaustion may be related to anemia, inflammation, disrupted sleep, or advanced disease. The kidneys help regulate red blood cell production, so a kidney tumor can sometimes contribute to an abnormally low red blood cell count.
Fever, night sweats, or leg swelling
Additional possible signs include unexplained fever, recurring night sweats, swelling around the ankles, or a general decline in stamina. These symptoms are nonspecific, but they deserve attention when persistent or combined with urinary changes, weight loss, or flank pain.
Symptoms of advanced disease
When kidney cancer spreads, symptoms depend on the affected organs. Lung metastases may cause coughing or shortness of breath. Bone involvement may produce persistent pain or fractures. Brain metastases can cause headaches, weakness, confusion, seizures, or changes in vision. These problems require prompt medical assessment.
When Should a Man See a Doctor?
Arrange a medical evaluation for visible blood in the urine, persistent one-sided flank pain, unexplained weight loss, a new abdominal mass, or symptoms that continue without a clear explanation. Seek urgent care for heavy urinary bleeding, blood clots that make urination difficult, severe pain, fainting, new neurological symptoms, or significant shortness of breath.
There is currently no recommended routine kidney cancer screening test for people at average risk. Men with inherited kidney cancer syndromes or particularly strong family histories may need periodic imaging under specialist supervision.
Major Risk Factors for Kidney Cancer in Men
A risk factor raises the probability of developing cancer; it does not guarantee that cancer will occur. Some men with several risk factors never develop kidney cancer, while others receive a diagnosis without any obvious explanation.
Smoking
Tobacco smoke contains carcinogens that enter the bloodstream and are filtered through the kidneys. Smoking increases kidney cancer risk, and heavier or longer exposure generally produces greater risk. Quitting helps reduce that risk over time while also benefiting the lungs, heart, circulation, and nearly every person who has ever asked someone not to smoke near a doorway.
Excess body weight
Overweight and obesity are associated with kidney cancer. Possible explanations include altered hormone levels, chronic inflammation, insulin resistance, and metabolic changes that encourage abnormal cell growth.
High blood pressure
Hypertension is consistently linked to an increased kidney cancer risk. Researchers continue to study how much of the association comes from high blood pressure itself and whether particular medications contribute. Prescribed blood pressure medicine should never be stopped because of this association; uncontrolled hypertension carries immediate, well-established dangers.
Older age and male sex
Risk rises with age, and men develop kidney cancer at about twice the rate observed in women. These factors cannot be changed, but they can influence how seriously a clinician evaluates symptoms and family history.
Family history and inherited syndromes
Risk is higher when a close biological relative has had kidney cancer, particularly when multiple relatives are affected or diagnoses occurred at young ages. Inherited conditions associated with RCC include von Hippel-Lindau disease, Birt-Hogg-Dubé syndrome, hereditary papillary renal carcinoma, hereditary leiomyomatosis and renal cell carcinoma, and tuberous sclerosis complex.
Genetic counseling may be appropriate for men diagnosed unusually young, those with tumors in both kidneys, people with multiple kidney tumors, or anyone whose family history suggests a hereditary pattern.
Long-term kidney disease and dialysis
People with advanced chronic kidney disease, especially those receiving long-term dialysis who develop acquired kidney cysts, have a higher risk of certain kidney tumors. Their medical teams may recommend individualized monitoring.
Occupational and environmental exposures
Prolonged exposure to substances such as trichloroethylene and certain heavy metals has been associated with kidney cancer. Potentially affected occupations include metal manufacturing, painting, rubber production, degreasing, pavement work, petroleum-related work, and some military or industrial jobs. Proper ventilation, protective equipment, and workplace safety procedures are not optional accessories.
Sickle cell trait
Sickle cell trait is strongly associated with renal medullary carcinoma, an extremely rare but aggressive kidney cancer that often affects younger people. Blood in the urine in a person with sickle cell trait should be evaluated rather than automatically attributed to the trait itself.
Long-term misuse of certain pain relievers
Heavy or prolonged misuse of some pain medicines has been linked to renal injury and kidney cancer. Occasional, label-directed use is different from excessive long-term consumption. Men with reduced kidney function should ask a clinician which pain relievers are safest for them.
How Kidney Cancer Is Diagnosed
Evaluation typically begins with a discussion of symptoms, medications, smoking history, workplace exposure, prior kidney problems, and family cancer history. Testing may then include the following:
- Urinalysis: Detects visible or microscopic blood, protein, infection markers, and other abnormalities.
- Blood tests: Measure kidney function, red blood cell levels, calcium, liver function, and other indicators of general health.
- Ultrasound: Helps distinguish solid tumors from fluid-filled cysts.
- CT scan: Shows a mass’s size, position, blood supply, and possible spread to nearby tissues or organs.
- MRI: Provides detailed soft-tissue images and may be used when CT contrast is unsuitable or when blood-vessel involvement needs clarification.
- Biopsy: Removes a small tissue sample with a needle for laboratory analysis.
A biopsy is not required before every kidney operation. Imaging may provide enough information to proceed directly to surgery, particularly when a mass looks highly suspicious and removal is already recommended. Biopsy is more likely when the diagnosis is uncertain, active surveillance or ablation is being considered, or drug treatment is planned.
Stages of Kidney Cancer
Staging describes how far the disease has progressed:
- Stage I: The tumor is no more than 7 centimeters across and remains within the kidney.
- Stage II: The tumor is larger than 7 centimeters but is still confined to the kidney.
- Stage III: Cancer has entered major nearby veins, surrounding tissue, or regional lymph nodes but has not reached distant organs.
- Stage IV: Cancer has grown beyond nearby tissues or has spread to distant areas such as the lungs, bones, liver, or brain.
U.S. data show a five-year relative survival rate above 93% for localized kidney and renal pelvis cancer. Survival statistics describe large populations, not a stopwatch assigned to an individual. Tumor subtype, grade, overall health, treatment response, and new therapies can substantially affect a person’s outlook.
Treatment Options for Male Kidney Cancer
Treatment depends on tumor size, stage, subtype, location, kidney function, other health conditions, and the patient’s priorities. Ideally, decisions involve a multidisciplinary team that may include a urologic oncologist, medical oncologist, radiation oncologist, radiologist, pathologist, nephrologist, genetic counselor, and supportive-care specialists.
Active surveillance
Some small kidney masses grow very slowly and may never become dangerous, especially in older adults or people for whom surgery presents substantial risk. Active surveillance uses scheduled imaging and clinical visits to track the tumor. It is organized monitoring, not ignoring the cancer and hoping it becomes bored.
Partial nephrectomy
A partial nephrectomy removes the tumor and a small margin of surrounding tissue while preserving the rest of the kidney. It is commonly preferred for smaller localized tumors when technically feasible because it provides cancer control while protecting kidney function.
Radical nephrectomy
A radical nephrectomy removes the entire affected kidney and sometimes nearby tissue, the adrenal gland, or lymph nodes when clinically necessary. It may be recommended for large tumors, centrally located masses, or tumors that cannot be safely removed with a partial operation.
Both partial and radical nephrectomy may be performed through open, laparoscopic, or robotic-assisted surgery. A person can usually live well with one healthy kidney, although long-term blood pressure and kidney function monitoring remain important.
Ablation
Cryoablation freezes tumor cells, while radiofrequency or microwave ablation destroys them using heat. These minimally invasive treatments may be suitable for selected small tumors, patients with limited kidney reserve, or people who are not good candidates for major surgery.
Immunotherapy
Immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Medications such as pembrolizumab, nivolumab, and ipilimumab may be used alone or in combinations, depending on the stage and clinical situation.
Immune-related side effects can affect the skin, intestines, lungs, liver, thyroid, adrenal glands, kidneys, or other organs. New diarrhea, breathing trouble, severe fatigue, rash, yellowing of the skin, or unusual weakness should be reported promptly rather than saved for the next routine appointment.
Targeted therapy
Targeted medicines interfere with pathways kidney tumors use to grow blood vessels and survive. Examples include cabozantinib, axitinib, lenvatinib, pazopanib, sunitinib, and tivozanib. Possible side effects include high blood pressure, diarrhea, fatigue, mouth soreness, appetite changes, skin problems, and hand-foot syndrome.
Belzutifan targets a protein called HIF-2 alpha and is used in selected renal cell carcinoma settings. In June 2026, the U.S. Food and Drug Administration approved belzutifan with pembrolizumab as adjuvant treatment for certain adults with clear-cell RCC at intermediate-high or high risk of recurrence after surgery. The option applies to a specific patient group and is not a universal post-surgery regimen.
Radiation therapy
Traditional RCC is not usually treated primarily with radiation. However, highly focused radiation may control selected tumors or metastases and relieve pain, bleeding, neurological symptoms, or pressure on nearby tissues.
Chemotherapy
Conventional chemotherapy is generally ineffective against common clear-cell RCC and is not routinely used. It may be appropriate for certain uncommon kidney cancer subtypes, including collecting duct carcinoma and renal medullary carcinoma. Accurate pathology is therefore essential before anyone assumes that all kidney tumors follow the same treatment playbook.
Recovery and Life After Treatment
Recovery after kidney surgery varies with the procedure and the patient’s health. Early priorities include walking, breathing exercises, pain control, incision care, constipation prevention, hydration, and avoiding heavy lifting until the surgeon provides clearance.
Follow-up may include physical examinations, blood pressure checks, kidney function tests, and periodic chest and abdominal imaging. The schedule depends on tumor stage, pathology, treatment, and recurrence risk.
Protecting the remaining kidney function
- Control high blood pressure and diabetes.
- Avoid smoking and secondhand smoke.
- Maintain a sustainable, healthy body weight.
- Stay active as treatment and recovery allow.
- Discuss over-the-counter pain relievers and supplements with a clinician.
- Avoid dehydration, especially during vomiting, diarrhea, heat exposure, or strenuous activity.
- Complete recommended blood, urine, and imaging follow-ups.
Most people with one normally functioning kidney do not require dialysis or an extreme “kidney diet.” Dietary restrictions should be based on laboratory results, kidney function, blood pressure, and professional guidancenot a dramatic internet detox involving six gallons of celery juice.
Can Kidney Cancer Be Prevented?
No strategy can prevent every case, especially those influenced by age or inherited mutations. Men can still reduce several modifiable risks by quitting tobacco, managing blood pressure, maintaining a healthy weight, following workplace chemical protections, and using medications responsibly.
Regular primary care also matters. Blood pressure, kidney function, medication use, smoking status, and family history can be reviewed before symptoms become urgent. Men with strong family histories or suspected genetic syndromes should ask whether genetic counseling and individualized surveillance are appropriate.
Experience Section: What the Kidney Cancer Journey Can Feel Like
The following is a fictional composite based on common experiences reported by patients and clinical care teams. It does not represent one identifiable person or predict how every diagnosis will unfold.
Imagine a 58-year-old man named Mark who notices that his urine looks slightly pink one morning. It does not hurt, and the color is normal by lunchtime. He decides it was probably dehydration, a hard workout, or something he ate. Two weeks later, it happens again.
Mark is not terrified at first. Mostly, he is annoyed. He has meetings, family responsibilities, and a talent for placing medical appointments somewhere below cleaning the garage on his priority list. His partner eventually persuades him to call his primary care physician.
A urine test confirms blood but shows no clear infection. Blood tests indicate that his kidneys are still functioning normally. A CT scan is ordered, and the result identifies a small solid mass on one kidney. Suddenly, the conversation changes from “It is probably nothing” to “We need a urologist.”
The waiting period is emotionally difficult. Mark reads too much at midnight, discovers outdated survival statistics, and briefly becomes convinced that every back twinge is metastatic disease. At his specialist appointment, he learns that the mass appears localized and may be removable with a partial nephrectomy.
That explanation helps, but relief and fear coexist. He is grateful the tumor was discovered early while simultaneously furious that it exists at all. He worries about anesthesia, pain, work, kidney failure, and whether his sons inherited some mysterious genetic time bomb. His doctor explains that most kidney cancers are not caused by inherited syndromes, although Mark’s age, tumor characteristics, and family history will determine whether genetic counseling is worthwhile.
Mark undergoes robotic-assisted partial nephrectomy. The first days are less cinematic than he imagined. There are no heroic speechesjust soreness, short walks, naps, careful meals, and considerable appreciation for whoever invented supportive pillows. He learns that fatigue can last longer than the visible incisions suggest.
The pathology report confirms clear-cell RCC with favorable features and clean surgical margins. No additional drug treatment is recommended. Instead, Mark enters surveillance with periodic scans and laboratory testing.
Surveillance creates a new emotional rhythm. Before each scan, he becomes restless and irritable. After a reassuring result, he relaxes for several months. His care team tells him that “scanxiety” is common and suggests practical strategies: schedule the follow-up appointment soon after imaging, avoid searching symptoms late at night, write down questions, and bring a trusted person to important visits.
Mark also becomes more attentive to blood pressure, hydration, weight, and medication use. He quits smoking after several previous attempts, partly because the diagnosis turns an abstract health warning into something uncomfortably personal. He does not become a perfect wellness mascot. He still enjoys barbecue, misses workouts, and complains about taking his blood pressure. The difference is that he now treats preventive care as maintenance rather than punishment.
Another man’s experience could be very different. Someone with advanced disease may have months or years of immunotherapy, targeted treatment, dose adjustments, scans, and side-effect management. Treatment may pause because of inflammation, high blood pressure, diarrhea, fatigue, or liver test changes. A medication that works well for one patient may not work for another.
The practical lesson is that kidney cancer care is rarely a single dramatic event. It is a sequence of decisions: which specialist to see, whether a biopsy is needed, how much kidney tissue can be preserved, whether systemic therapy is appropriate, how side effects should be managed, and how ordinary life can continue around medical uncertainty.
Support can make those decisions less isolating. A partner may track medications, a friend may provide transportation, a social worker may assist with employment or insurance concerns, and a counselor or support group may help with fear that feels too heavy for casual conversation. Asking for that help is not weakness. Cancer is already doing enough work; it does not need to be accompanied by a one-man performance of emotional invincibility.
Conclusion
Kidney cancer is more common in men, but its early warning system is frustratingly quiet. Visible blood in the urine, persistent flank pain, unexplained weight loss, fatigue, anemia, or a new abdominal lump should be evaluated rather than dismissed.
Smoking, excess body weight, high blood pressure, older age, family history, inherited syndromes, long-term kidney disease, sickle cell trait, and occupational chemical exposure can increase risk. Treatment ranges from active surveillance and kidney-sparing surgery to ablation, immunotherapy, targeted drugs, radiation, and specialized therapy for rare subtypes.
Early-stage kidney cancer is often highly treatable, and treatment for advanced disease continues to improve. The most useful step is not trying to diagnose a symptom aloneit is getting the right evaluation while there are still as many options as possible.
